agilon health, inc. AGL R2K
Healthcare · Medical Care Facilities · United States
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Westerville, Ohio.
READ MORE ›$92.28
+66.27% 1Y
Market & Price
Market Cap
$1.54B
Current Price
$92.28
High / Low (52W)
$92.28 / $7.91
Beta
2.31
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$10.93
Price to Book
8.45
P/S
0.26
EV/EBITDA
-3.58
Dividend Yield
-
Profitability & Returns
ROCE
-
ROE
-109.59%
ROA
-14.16%
Profit Margin
-6.09%
Op Margin
0.71%
EPS (Latest Qtr)
$2.94
EPS (TTM)
$-22.59
Balance Sheet & Liquidity
Debt/Equity
0.18
Quick Ratio
0.92
Current Ratio
1.04
Debt
$33.40M
Total Assets
$1.27B
Current Assets
$1.10B
Working Capital
$20.21M
Ownership
Promoter Holding
3.10%
Chg in Prom Hold
-
FII / Inst Holding
92.44%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$1.34B
Total Revenue (TTM)
$5.82B
EBITDA
$-374.58M
Free Cash Flow
$-104.21M
Operating Cash Flow
$-50.05M
Shares Outstanding
16.68M
Gross Margin
-2.50%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
35.43%
Profit 5Y
-89.09%
Revenue (YoY)
-7.30%
Earnings (YoY)
301.00%
PROS
- Compounding revenue at 35.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -89.1% CAGR over 5 years.
- RSI at 79 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AGL agilon health, inc. R2K | 92.28 | - | $1.54B | - | - | -109.59% | 35.43% | -89.09% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 291.05M | 293.59M | 312.68M | 413.10M | 498.96M | 458.61M | 653.45M | 670.13M | 694.86M | 1.05B | 1.07B | 1.14B | 1.60B | 1.48B | 1.45B | - | 1.53B | 1.39B | 1.44B | 1.57B | 1.42B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.48B | 1.45B | 1.50B | 1.66B | 1.36B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.72M | -52.43M | -67.65M | -90.67M | 65.02M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.83M | 63.60M | 63.63M | 67.07M | 61.02M |
| Operating Income | -5.83M | -1.25M | -9.84M | -12.12M | -298.36M | -35.60M | -743.00K | -21.05M | -29.52M | 417.00K | -28.96M | -39.29M | -7.18M | -43.34M | -133.51M | - | -22.11M | -116.03M | -131.27M | -157.74M | 4.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.70M | -95.42M | -101.27M | -178.87M | 38.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.51M | 1.57M | 1.84M | 1.72M | 1.81M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.69M | -104.31M | -110.54M | -187.56M | 29.94M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 196.00K | 62.00K | -331.00K | 1.32M | 28.00K |
| Net Income | -16.10M | -7.91M | -11.83M | -15.08M | -298.85M | -35.84M | 1.23M | -20.65M | -30.67M | 16.02M | -16.75M | -31.44M | -6.06M | -30.68M | -117.61M | - | 12.11M | -104.37M | -110.21M | -188.88M | 48.92M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73 | -6.25 | -6.75 | -11.50 | 2.94 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 794.41M | 1.22B | 1.52B | 2.39B | 4.32B | 6.06B | 5.93B |
| Cost of Revenue | - | - | - | 2.28B | 4.25B | 6.06B | 6.09B |
| Gross Profit | - | - | - | 111.36M | 69.67M | 4.84M | -160.02M |
| Operating Expenses | - | - | - | 216.74M | 301.80M | 293.38M | 267.13M |
| Operating Income | -106.57M | -56.67M | -372.24M | -105.38M | -232.13M | -288.53M | -427.15M |
| EBITDA | - | - | - | -72.41M | -167.64M | -218.19M | -368.86M |
| Interest Expense | - | - | - | 4.48M | 6.66M | 6.18M | 6.64M |
| Pretax Income | - | - | - | -90.67M | -194.46M | -248.83M | -404.10M |
| Tax Provision | - | - | - | 1.64M | 791.00K | 1.45M | 1.25M |
| Net Income | -282.59M | -60.05M | -406.49M | -106.55M | -262.60M | -260.15M | -391.35M |
| Diluted EPS | - | - | - | -6.50 | -16.00 | -15.75 | -23.75 |
Compounded Sales Growth
| 5 Years: | 35.43% |
| 1 Year: | -7.30% |
Compounded Profit Growth
| 5 Years: | -89.09% |
| 1 Year: | 301.00% |
Stock Price Performance
| 1 Year: | +66.27% |
| 6 Months: | +477.65% |
| 3 Months: | +526.69% |
| 1 Month: | +230.87% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 446.36M | - | 1.70B | 1.74B | 1.73B | 1.27B |
| Current Assets | - | - | - | - | 1.45B | 1.48B | 1.46B | 1.10B |
| Cash & Equivalents | - | - | 106.80M | - | 465.30M | 107.57M | 188.23M | 173.71M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 492.36M | 942.46M | 1.02B | 673.79M |
| Total Liabilities | - | - | 421.59M | - | 656.86M | 1.08B | 1.26B | 1.14B |
| Current Liabilities | - | - | 266.83M | - | 535.09M | 977.16M | 1.15B | 1.08B |
| Long Term Debt | - | - | 64.67M | - | 38.48M | 32.31M | 34.90M | 15.75M |
| Total Debt | - | - | - | - | 52.57M | 43.21M | 41.50M | 36.81M |
| Total Equity | 41.60M | -232.03M | -284.73M | - | 1.04B | 661.84M | 470.95M | 126.73M |
| Shares Outstanding | - | - | - | - | 16.50M | 16.26M | 16.49M | 16.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -103.86M | -53.20M | - | -130.81M | -156.20M | -57.78M | -105.76M |
| Investing Cash Flow | -5.06M | 22.07M | - | -444.39M | -44.02M | 139.89M | 88.61M |
| Financing Cash Flow | 176.30M | 24.62M | - | 28.06M | -193.13M | -2.58M | -2.99M |
| Capital Expenditure | -2.89M | -1.77M | - | -32.66M | -30.82M | -41.28M | -43.11M |
| Free Cash Flow | -106.75M | -54.98M | - | -163.47M | -187.01M | -99.06M | -148.87M |
| Net Change in Cash | - | - | - | -547.14M | -393.35M | 79.53M | -20.15M |
| Share Buybacks | - | 6.70M | - | - | 200.00M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 4.7% | 1.6% | 0.1% | -2.7% |
| Operating Margin % | -13.4% | -4.7% | -24.5% | -4.4% | -5.4% | -4.8% | -7.2% |
| Net Margin % | -35.6% | -4.9% | -26.7% | -4.5% | -6.1% | -4.3% | -6.6% |
| ROE % | 121.8% | 21.1% | - | -10.2% | -39.7% | -55.2% | -308.8% |
| ROCE % | - | -31.6% | - | -9.1% | -30.4% | -49.6% | -219.3% |
Shareholding Pattern
Insiders
3.10%
Institutions
92.44%
Public Float
95.40%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Clayton, Dubilier & Rice, LLC | 23.98% | 4.00M | $369.12M |
| 2 | Morgan Stanley | 12.58% | 2.10M | $193.74M |
| 3 | North Peak Capital Management, Llc | 9.26% | 1.55M | $142.62M |
| 4 | Goldman Sachs Group Inc | 6.37% | 1.06M | $98.02M |
| 5 | AQR Capital Management, LLC | 5.84% | 974.90K | $89.96M |
| 6 | Blackrock Inc. | 5.23% | 873.16K | $80.58M |
| 7 | Shaw D.E. & Co., Inc. | 4.45% | 742.22K | $68.49M |
| 8 | Vanguard Capital Management LLC | 3.23% | 538.54K | $49.70M |
| 9 | Charles Schwab Investment Management, Inc. | 2.18% | 364.50K | $33.64M |
| 10 | Jacobs Levy Equity Management, Inc. | 1.78% | 296.55K | $27.37M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AGL
No recent headlines available.